Skip to main content

Table 1 Baseline characteristics of the study population in training set (Huai’an, Jilin and Anhui) and in validation sets (Beijing)

From: FibroBox: a novel noninvasive tool for predicting significant liver fibrosis and cirrhosis in HBV infected patients

Variables

Huai’an (n = 252)

Jilin (n = 297)

Anhui (n = 408)

Beijing (n = 332)

p Value

Male sex, n

158 (63%)

168 (57%)

257 (63%)

203 (61%)

0.274

Median age (years) (IQR)

42 (32–49)

42 (33–50)

38 (29–48)

38 (30–47)

0.006

Median BMI (kg/m2) (IQR)

23.7 (22.5–25.1)

23.7 (21.6–26.0)

22.8 (20.4–25.4)

23.7 (21.0–26.1)

0.014

Median fasting LSM value (kPa)

10.4 (6.6–15.3)

7.9 (5.9–11.8)

5.7 (4.2–7.5)

7.8 (5.6–12.4)

<  0.001

Median ALT (IU/L) (IQR)

42 (27–67)

39 (24–65)

49 (26–84.5)

46.2 (25.2–79.4)

0.046

Median AST (IU/L) (IQR)

35 (27–55)

32 (25–50)

34 (23–51)

33 (25–52)

0.108

Median GGT (IU/L) (IQR)

46 (24–98)

37 (21–79)

31.5 (21–73)

32 (19–60)

<  0.001

Median total bilirubin (IU/L) (IQR)

15.8 (11.9–21.0)

14.4 (11.6–21.2)

17.7 (13.0–23.1)

14.3 (11.4–20)

0.654

Median platelet counts (109/L) (IQR)

165 (122–206)

179 (140–215)

161.5 (125–204)

186 (148–225)

0.148

Median APRI (IQR)

0.64 (0.41–1.35)

0.51 (0.33–0.84)

0.55 (0.34–0.92)

0.50 (0.30–0.76)

<  0.001

Median FIB-4 (IQR)

1.61 (0.99–2.87)

1.22 (0.82–1.95)

1.17 (0.74–2.04)

1.07 (0.73–1.69)

<  0.001

Ultrasound size of spleen (mm2) (IQR)

4410 (3866–5280)

3780 (2976–4710)

3468 (3120–3813)

3620 (2890–4560)

<  0.001

Ultrasound diameter of spleen vein (mm) (IQR)

6 (5.2–7)

7 (6.7–8)

9 (8–10)

7 (6–8)

<  0.001

Ultrasound diameter of portal vein (mm) (IQR)

11 (10–12)

12 (11–12)

11 (10–11)

11 (10–12)

<  0.001

Ultrasound velocity of portal vein (m/s) (IQR)

0.16 (0.14–0.19)

0.11 (0.10–0.12)

Not reported

Not reported

 

Median size of liver biopsy (mm) (IQR)

15 (12–16)

16 (12–19)

15 (12–20)

16 (13–18)

<  0.001

Metavir fibrosis stage (F0/F1/F2/F3/F4)

21 (8.3%)/37 (14.7%)/46 (18.3%)/51 (20.2%)/97 (38.5%)

32 (10.8%)/77 (25.9%)/84 (28.3%)/44 (14.8%)/60 (20.2%)

10 (2.5%)/144 (35.3%)/129 (31.6%)/66 (16.2%)/59 (14.5%)

26 (7.9%)/127 (38.3%)/73 (22%)/32 (9.6%)/74 (22.3%)

<  0.001

Metavir activity grade (A0/A1/A2/A3)

50 (19.8%)/106 (42.1%)/72 (28.6%)/24 (9.5%)

190 (64.0%)/54 (18.2%)/52 (17.5%)/1 (0.3%)

86 (21.1%)/254 (62.2%)/61 (15.0%)/7 (1.7%)

13 (3.9%)/154 (46.4%)/114 (34.3%)/51 (15.4%)

<  0.001

  1. ALT alanine transaminase, APRI (AST)-to-platelet ratio index, AST aspartate transaminase, BMI body mass index, GGT gamma-glutamyl transpeptidase, LSM liver stiffness measurement